ALDH18A1 and telomere syndrome: Then, we evaluated the predictive ability of the GPR-TME classifier in the immunotherapy response from TIDE; the GPRlow/TMEhigh subgroup had the highest percentage (38%) of patients with immunotherapy response among all subgroups, and the immunotherapy responder of STS presented a significantly lower GPR score but no significant difference in the TME score between the two groups, indicating that the GPR score can independently affect the outcome of immunotherapy (Figures 12G, H).